Search

Your search keyword '"Schultheiss, Michael"' showing total 351 results
Start Over Author "Schultheiss, Michael"
351 results on '"Schultheiss, Michael"'

3. Evaluation of Laboratory and Sonographic Parameters for Detection of Portal Hypertension in Patients with Common Variable Immunodeficiency.

Author

Kindle, Gerhard, Goldacker, Sigune, von Spee-Mayer, Caroline, Proietti, Michele, Bausch, Birke, Bettinger, Dominik, Schultheiß, Michael, Thimme, Robert, Schuppan, Detlef, Warnatz, Klaus, Globig, Anna-Maria, Strohmeier, Valentina, Surabattula, Rambabu, Leeming, Diana, Karsdal, Morten, and Heeg, Maximilian

Subjects
Common variable immunodeficiency, diagnosis, hepatopathy, nodular regenerative hyperplasia, portal hypertension, Humans, Common Variable Immunodeficiency, Hypertension, Portal, Esophageal and Gastric Varices, Elasticity Imaging Techniques, Liver Cirrhosis, Liver
Abstract

Timely detection of portal hypertension as a manifestation in a subgroup of patients with common variable immunodeficiency (CVID) represents a challenge since it is usually not associated with liver cirrhosis. To identify relevant markers for portal hypertension, we evaluated clinical history, laboratory parameters, and abdominal ultrasound including liver elastography and biomarkers of extracellular matrix formation. Twenty seven (6%) of 479 CVID patients presented with clinically significant portal hypertension as defined by either the presence of esophageal varices or ascites. This manifestation occurred late during the course of the disease (11.8 years after first diagnosis of CVID) and was typically part of a multiorgan disease and associated with a high mortality (11/27 patients died during follow up). The strongest association with portal hypertension was found for splenomegaly with a longitudinal diameter of > 16 cm. Similarly, most patients presented with a liver stiffness measurement (LSM) of above 6.5 kPa, and a LSM above 20 kPa was always indicative of manifest portal hypertension. Additionally, many laboratory parameters including Pro-C4 were significantly altered in patients with portal hypertension without clearly increasing the discriminatory power to detect non-cirrhotic portal hypertension in CVID. Our data suggest that a spleen size above 16 cm and an elevated liver stiffness above 6.5 kPa should prompt further evaluation of portal hypertension and its sequelae, but earlier and better liquid biomarkers of this serious secondary complication in CVID are needed.

Published
2022

5. Evaluation of Laboratory and Sonographic Parameters for Detection of Portal Hypertension in Patients with Common Variable Immunodeficiency

Author

Globig, Anna-Maria, Strohmeier, Valentina, Surabattula, Rambabu, Leeming, Diana J., Karsdal, Morten A., Heeg, Maximilian, Kindle, Gerhard, Goldacker, Sigune, von Spee-Mayer, Caroline, Proietti, Michele, Bausch, Birke, Bettinger, Dominik, Schultheiß, Michael, Thimme, Robert, Schuppan, Detlef, and Warnatz, Klaus

Published
2022
Full Text
View/download PDF

8. OS-112-YI Outcome and management of patients with hepatocellular carcinoma who achieved complete response to immunotherapybased systemic therapy

Author

Scheiner, Bernhard, primary, Kang, Beodeul, additional, Balcar, Lorenz, additional, Radu, Pompilia, additional, Reiter, Florian P, additional, Adžić, Gordan, additional, Guo, Jiang, additional, Gao, Xu, additional, Yuan, Xiao, additional, Cheng, Long, additional, Gorgulho, Joao, additional, Schultheiß, Michael, additional, Khaled, Najib Ben, additional, Sinner, Friedrich, additional, D'Alessio, Antonio, additional, Pomej, Katharina, additional, Saborowski, Anna, additional, Schwacha-Eipper, Birgit, additional, Zarka, Valentina, additional, Lampichler, Katharina, additional, Nishida, Naoshi, additional, Lee, Pei-Chang, additional, Krall, Anja, additional, Saeed, Anwaar, additional, Himmelsbach, Vera, additional, Tesini, Giulia, additional, Wietharn, Brooke, additional, Huang, Yi-Hsiang, additional, Vivaldi, Caterina, additional, Masi, Gianluca, additional, Vogel, Arndt, additional, Schulze, Kornelius, additional, Trauner, Michael, additional, Stauber, Rudolf E., additional, Kudo, Masatoshi, additional, Dekervel, Jeroen, additional, Parikh, Neehar, additional, Dufour, Jean-François, additional, Prejac, Juraj, additional, Geier, Andreas, additional, Bengsch, Bertram, additional, von Felden, Johann, additional, Venerito, Marino, additional, Philipp, Alexander, additional, Finkelmeier, Fabian, additional, Ji, Fanpu, additional, Wang, Hung-Wei, additional, Rimassa, Lorenza, additional, Pinato, David J., additional, Bouattour, Mohamed, additional, Chon, Hong Jae, additional, and Pinter, Matthias, additional

Published
2024
Full Text
View/download PDF

10. Aspirin improves transplant-free survival after TIPS implantation in patients with refractory ascites: a retrospective multicentre cohort study

Author

Seifert, Leon Louis, Schindler, Philipp, Sturm, Lukas, Gu, Wenyi, Seifert, Quentin Edward, Weller, Jan Frederic, Jansen, Christian, Praktiknjo, Michael, Meyer, Carsten, Schoster, Martin, Wilms, Christian, Maschmeier, Miriam, Schmidt, Hartmut H., Masthoff, Max, Köhler, Michael, Schultheiss, Michael, Huber, Jan Patrick, Bettinger, Dominik, Trebicka, Jonel, Wildgruber, Moritz, and Heinzow, Hauke

Published
2022
Full Text
View/download PDF

15. Percutaneous transcatheter aspiration of pulmonary embolism leading to diagnosis of hepatocellular carcinoma tumor embolus and change in systemic chemotherapy.

Author

Verloh, Niklas, Vogt, Katharina, Bettinger, Dominik, Schultheiß, Michael, Kandilaris, Kosmas, Holzner, Philipp A., Doppler, Michael C., and Uller, Wibke

Subjects
CANCER chemotherapy, RESPIRATORY aspiration, HEPATOCELLULAR carcinoma, PULMONARY embolism, DIAGNOSIS, PULMONARY artery
Abstract

The management of metastatic hepatocellular carcinoma (HCC) is complex, particularly when complicated by pulmonary embolism. In these cases, atezolizumab-bevacizumab therapy is contraindicated due to an elevated risk of thromboembolic events. Differentiating pulmonary tumor embolism from thromboembolic disease is diagnostically challenging. This report outlines the benefit of transcatheter aspiration to obtain pathological evidence of pulmonary artery tumor embolus in anHCC patient. The intervention enabled a significant shift in the management strategy, leading to an escalation of systemic HCC therapy. This case underscores the importance of precise diagnostic techniques such as transcatheter aspiration in guiding treatment decisions, particularly in cases where pulmonary embolism may signify an underlying malignancy-driven process. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

20. Doxorubicin-loaded nanoparticles for patients with advanced hepatocellular carcinoma after sorafenib treatment failure (RELIVE): a phase 3 randomised controlled trial

Author

Moussata, Driffa, Grangé, Jean-Didier, Ratziu, Vlad, Khemissa-Akouz, Faiza, Regnault, Hélène, Dauvois, Barbara, Zarski, Jean-Pierre, Ollivier-Hourmand, Isabelle, Manfredi, Sylvain, Debette-Gratien, Marilyne, Gangloff, Alice, Fontanges, Thierry, Baron, Aurore, Bouattour, Mohamed, Vincent, Julie, Sieghart, Wolfgang, Maieron, Andreas, Peeters, Marc, Delwaide, Jean, Lasser, Luc, Berg, Thomas, Schultheiß, Michael, Zipprich, Alexander, Trojan, Joerg, Ehmer, Ursula, Luppi, Gabriele, Luca, Giovanni, Tamberi, Stefano, Amoroso, Domenico, Alabiso, Oscar, Buonadonna, Angela, Toniutto, Pierluigi, Tamburini, Emiliano, Cubillo, Antonio, Muñoz, Andrés, Guillén, Carmen, Sánchez, Gloria, Manzano, Hermini, Navarro, Victor, Ales, Inmaculada, Massuti, Bartomeu, Dank, Magdolna, Bodoky, György, Kahan, Zsuzsanna, Horváth, Zsolt, Gabrail, Nashat, Ozer, Howard, Galanopoulos, Christos, Hauke, Ralph, Raj, Moses, Harputluoglu, Hakan, Sevinc, Alper, Goker, Erdem, Coker, Ahmet, Yalcin, Suayib, Ali, Muhammet, Ata, Ozlem, Tugba, Ilkay, El Kassas, Mohammed, Abdel, Amr, Wakid, Imam, Shamaa, Sameh, El Lahlouby, Nasr, Kohail, Hanaa, Makarem, Jawad, Chehade, Issam, Farhat, Fadi, López, Carlos, Marín, Miguel, Merle, Philippe, Blanc, Jean-Frederic, Phelip, Jean-Marc, Pelletier, Gilles, Bronowicki, Jean-Pierre, Touchefeu, Yann, Pageaux, Georges, Gerolami, René, Habersetzer, François, Nguyen-Khac, Eric, Casadei-Gardini, Andrea, Borbath, Ivan, Tran, Albert, Wege, Henning, Saad, Amr Shafik, Colombo, Massimo, Abergel, Armand, Richou, Carine, Waked, Imam, Yee, Nelson S, Molé, Audrey, Attali, Pierre, Le Boulicaut, Julie, and Vasseur, Bérangère

Published
2019
Full Text
View/download PDF

23. Prediction of postembolization syndrome after transarterial chemoembolization of hepatocellular carcinoma and its impact on prognosis

Author

Roehlen, Natascha, primary, Stoehr, Fabian, additional, Müller, Lukas, additional, Luxenburger, Hendrik, additional, Gairing, Simon J., additional, Reincke, Marlene, additional, Schultheiss, Michael, additional, Berisha, Floriona, additional, Weinmann, Arndt, additional, Foerster, Friedrich, additional, Marquardt, Jens U., additional, Thimme, Robert, additional, Galle, Peter R., additional, Bettinger, Dominik, additional, and Kloeckner, Roman, additional

Published
2023
Full Text
View/download PDF

24. Decreased Platelet Aggregation in Patients with Decompensated Liver Cirrhosis and TIPS Implantation

Author

Nassar, Asala, primary, Huber, Jan Patrick, additional, Stallmann, Daniela, additional, Sharipova, Diana, additional, Hamad, Muataz Ali, additional, Schultheiss, Michael, additional, Thimme, Robert, additional, Duerschmied, Daniel, additional, Scharf, Rüdiger Eberhard, additional, Bettinger, Dominik, additional, and Krauel, Krystin, additional

Published
2023
Full Text
View/download PDF

34. Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells

Author

Mathew, Nimitha R, Baumgartner, Francis, Braun, Lukas, O'Sullivan, David, Thomas, Simone, Waterhouse, Miguel, Müller, Tony A, Hanke, Kathrin, Taromi, Sanaz, Apostolova, Petya, Illert, Anna L, Melchinger, Wolfgang, Duquesne, Sandra, Schmitt-Graeff, Annette, Osswald, Lena, Yan, Kai-Li, Weber, Arnim, Tugues, Sonia, Spath, Sabine, Pfeifer, Dietmar, Follo, Marie, Claus, Rainer, Lübbert, Michael, Rummelt, Christoph, Bertz, Hartmut, Wäsch, Ralph, Haag, Johanna, Schmidts, Andrea, Schultheiss, Michael, Bettinger, Dominik, Thimme, Robert, Ullrich, Evelyn, Tanriver, Yakup, Vuong, Giang Lam, Arnold, Renate, Hemmati, Philipp, Wolf, Dominik, Ditschkowski, Markus, Jilg, Cordula, Wilhelm, Konrad, Leiber, Christian, Gerull, Sabine, Halter, Jörg, Lengerke, Claudia, Pabst, Thomas, Schroeder, Thomas, Kobbe, Guido, Rösler, Wolf, Doostkam, Soroush, Meckel, Stephan, Stabla, Kathleen, Metzelder, Stephan K, Halbach, Sebastian, Brummer, Tilman, Hu, Zehan, Dengjel, Joern, Hackanson, Björn, Schmid, Christoph, Holtick, Udo, Scheid, Christof, Spyridonidis, Alexandros, Stölzel, Friedrich, Ordemann, Rainer, Müller, Lutz P, Sicre-de-Fontbrune, Flore, Ihorst, Gabriele, Kuball, Jürgen, Ehlert, Jan E, Feger, Daniel, Wagner, Eva-Maria, Cahn, Jean-Yves, Schnell, Jacqueline, Kuchenbauer, Florian, Bunjes, Donald, Chakraverty, Ronjon, Richardson, Simon, Gill, Saar, Kröger, Nicolaus, Ayuk, Francis, Vago, Luca, Ciceri, Fabio, Müller, Antonia M, Kondo, Takeshi, Teshima, Takanori, Klaeger, Susan, Kuster, Bernhard, Weisdorf, Daniel, van der Velden, Walter, Dörfel, Daniela, Bethge, Wolfgang, Hilgendorf, Inken, Hochhaus, Andreas, Andrieux, Geoffroy, Börries, Melanie, Busch, Hauke, Magenau, John, Reddy, Pavan, Labopin, Myriam, Antin, Joseph H, Henden, Andrea S, Hill, Geoffrey R, Kennedy, Glen A, Bar, Merav, Sarma, Anita, McLornan, Donal, Mufti, Ghulam, Oran, Betul, Rezvani, Katayoun, Shah, Omid, Negrin, Robert S, Nagler, Arnon, Prinz, Marco, Burchert, Andreas, Neubauer, Andreas, Beelen, Dietrich, Mackensen, Andreas, von Bubnoff, Nikolas, Herr, Wolfgang, Becher, Burkhard, Socié, Gerard, Caligiuri, Michael A, Ruggiero, Eliana, Bonini, Chiara, Häcker, Georg, Duyster, Justus, Finke, Jürgen, Pearce, Erika, Blazar, Bruce R, and Zeiser, Robert

Subjects
Interleukin-15 -- Health aspects, Gene mutation -- Health aspects, Sorafenib -- Patient outcomes, Gene expression -- Health aspects, Acute myelocytic leukemia -- Genetic aspects -- Development and progression -- Drug therapy, Biological sciences, Health
Abstract

Individuals with acute myeloid leukemia (AML) harboring an internal tandem duplication (ITD) in the gene encoding Fms-related tyrosine kinase 3 (FLT3) who relapse after allogeneic hematopoietic cell transplantation (allo-HCT) have a 1-year survival rate below 20%. We observed that sorafenib, a multitargeted tyrosine kinase inhibitor, increased IL-15 production by FLT3-ITD[sup.+] leukemia cells. This synergized with the allogeneic CD8[sup.+] T cell response, leading to long-term survival in six mouse models of FLT3-ITD[sup.+] AML. Sorafenib-related IL-15 production caused an increase in CD8[sup.+]CD107a[sup.+]IFN-[gamma][sup.+] T cells with features of longevity (high levels of Bcl-2 and reduced PD-1 levels), which eradicated leukemia in secondary recipients. Mechanistically, sorafenib reduced expression of the transcription factor ATF4, thereby blocking negative regulation of interferon regulatory factor 7 (IRF7) activation, which enhanced IL-15 transcription. Both IRF7 knockdown and ATF4 overexpression in leukemia cells antagonized sorafenib-induced IL-15 production in vitro. Human FLT3-ITD[sup.+] AML cells obtained from sorafenib responders following sorafenib therapy showed increased levels of IL-15, phosphorylated IRF7, and a transcriptionally active IRF7 chromatin state. The mitochondrial spare respiratory capacity and glycolytic capacity of CD8[sup.+] T cells increased upon sorafenib treatment in sorafenib responders but not in nonresponders. Our findings indicate that the synergism of T cells and sorafenib is mediated via reduced ATF4 expression, causing activation of the IRF7-IL-15 axis in leukemia cells and thereby leading to metabolic reprogramming of leukemia-reactive T cells in humans. Therefore, sorafenib treatment has the potential to contribute to an immune-mediated cure of FLT3-ITD-mutant AML relapse, an otherwise fatal complication after allo-HCT., Author(s): Nimitha R Mathew [1, 2]; Francis Baumgartner [1]; Lukas Braun [1]; David O'Sullivan [3]; Simone Thomas [4]; Miguel Waterhouse [1]; Tony A Müller [1]; Kathrin Hanke [1, 2]; Sanaz [...]

Published
2018
Full Text
View/download PDF

36. Atezolizumab plus bevacizumab beyond first-line in hepatocellular carcinoma

Author

Sinner, Friedrich, additional, Pinter, Matthias, additional, Scheiner, Bernhard, additional, Ettrich, Thomas, additional, Sturm, Niklas, additional, Gonzalez-Carmona, MariaA., additional, Waidmann, Oliver, additional, Finkelmeier, Fabian, additional, Himmelsbach, Vera, additional, de Toni, EnricoN., additional, Ben-Khaled, Najib, additional, Mohr, Raphael, additional, Fründt, ThorbenWilhelm, additional, Kütting, Fabian, additional, van Bömmel, Florian, additional, Lieb, Sabine, additional, Krug, Sebastian, additional, Bettinger, Dominik, additional, Schultheiß, Michael, additional, Jochheim, Leonie, additional, Best, Jan, additional, Keitel, Verena, additional, Müller, Christian, additional, and Venerito, Marino, additional

Published
2023
Full Text
View/download PDF

39. Predictive Value of [ 99m Tc]-MAA-Based Dosimetry in Hepatocellular Carcinoma Patients Treated with [ 90 Y]-TARE: A Single-Center Experience.

Author

Doppler, Michael, Reincke, Marlene, Bettinger, Dominik, Vogt, Katharina, Weiss, Jakob, Schultheiss, Michael, Uller, Wibke, Verloh, Niklas, and Goetz, Christian

Subjects
MEDICAL dosimetry, PATIENT portals, PORTAL vein, OVERALL survival, LIVER tumors
Abstract

Transarterial radioembolization is a well-established method for the treatment of hepatocellular carcinoma. The tolerability and incidence of hepatic decompensation are related to the doses delivered to the tumor and healthy liver. This retrospective study was performed at our center to evaluate whether tumor- and healthy-liver-absorbed dose levels in TARE are predictive of tumor response according to the mRECIST 1.1 criteria and overall survival. One hundred and six patients with hepatocellular carcinoma were treated with [90Y]-loaded resin microspheres and completed the follow-up. The dose delivered to each compartment was calculated using a compartmental model. The model was based on [99mTc]-labelled albumin aggregate images obtained before the start of therapy. Tumor response was assessed after three months of treatment. Kaplan-Meier analysis was used to assess survival. The mean age of our population was 66 ± 13 years with a majority being BCLC B tumors. Forty-two patients presented with portal vein thrombosis. The response rate was 57% in the overall population and 59% in patients with thrombosis. Target-to-background (TBR) values measured on initial [99mTc]MAA-SPECT-imaging and tumor model dosimetric values were associated with tumor response (p < 0.001 and p = 0.009, respectively). A dosimetric threshold of 136.5 Gy was predictive of tumor response with a sensitivity of 84.2% and specificity of 89.4%. Overall survival was 24.1 months [IQR 13.1–36.4] for patients who responded to treatment compared to 10.4 months [IQR 6.3–15.9] for the remaining patients (p = 0.022). In this cohort, the initial [99mTc]MAA imaging is predictive of response and survival. The dosimetry prior to the application of TARE can be used for treatment planning and our results also suggest that the therapy is well-tolerated. In particular, hepatic decompensation can be predicted even in the presence of PVT. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

41. Survival prediction using the Freiburg index of post-TIPS survival (FIPS) in critically ill patients with acute- on chronic liver failure: A retrospective observational study

Author

Luxenburger, Hendrik, primary, Schmidt, Katharina, additional, Biever, Paul, additional, Supady, Alexander, additional, Sekandarzad, Asieb, additional, Roehlen, Natascha, additional, Reincke, Marlene, additional, Neumann-Haefelin, Christoph, additional, Schultheiss, Michael, additional, Wengenmayer, Tobias, additional, Thimme, Robert, additional, and Bettinger, Dominik, additional

Published
2022
Full Text
View/download PDF

42. Atezolizumab Plus Bevacizumab in Patients with Advanced and Progressing Hepatocellular Carcinoma: Retrospective Multicenter Experience

Author

Sinner, Friedrich, primary, Pinter, Matthias, additional, Scheiner, Bernhard, additional, Ettrich, Thomas Jens, additional, Sturm, Niklas, additional, Gonzalez-Carmona, Maria A., additional, Waidmann, Oliver, additional, Finkelmeier, Fabian, additional, Himmelsbach, Vera, additional, De Toni, Enrico N., additional, Ben Khaled, Najib, additional, Mohr, Raphael, additional, Fründt, Thorben Wilhelm, additional, Kütting, Fabian, additional, Bömmel, Florian van, additional, Lieb, Sabine, additional, Krug, Sebastian, additional, Bettinger, Dominik, additional, Schultheiß, Michael, additional, Jochheim, Leonie S., additional, Best, Jan, additional, Müller, Christian, additional, Keitel, Verena, additional, and Venerito, Marino, additional

Published
2022
Full Text
View/download PDF

44. T-cell exhaustion and residency dynamics inform clinical outcomes in hepatocellular carcinoma

Author

Barsch, Maryam, primary, Salié, Henrike, additional, Schlaak, Alexandra Emilia, additional, Zhang, Zhen, additional, Hess, Moritz, additional, Mayer, Lena Sophie, additional, Tauber, Catrin, additional, Otto-Mora, Patricia, additional, Ohtani, Takuya, additional, Nilsson, Tobias, additional, Wischer, Lara, additional, Winkler, Frances, additional, Manne, Sasikant, additional, Rech, Andrew, additional, Schmitt-Graeff, Annette, additional, Bronsert, Peter, additional, Hofmann, Maike, additional, Neumann-Haefelin, Christoph, additional, Boettler, Tobias, additional, Fichtner-Feigl, Stefan, additional, van Boemmel, Florian, additional, Berg, Thomas, additional, Rimassa, Lorenza, additional, Di Tommaso, Luca, additional, Saeed, Anwaar, additional, D’Alessio, Antonio, additional, Pinato, David J., additional, Bettinger, Dominik, additional, Binder, Harald, additional, John Wherry, E., additional, Schultheiss, Michael, additional, Thimme, Robert, additional, and Bengsch, Bertram, additional

Published
2022
Full Text
View/download PDF

45. Risk factors for short-term post discharge clinical outcomes in patients hospitalized with decompensated chronic liver disease: interim results from Global CLEARED study

Author

Bajaj, Jasmohan S., primary, Kamath, Patrick S., additional, Wong, Florence, additional, Hayes, Peter, additional, Idilman, Ramazan, additional, Torre, Aldo, additional, Topazian, Mark, additional, George, Jacob, additional, Álvares-da-Silva, Mario Reis, additional, Xie, Qing, additional, Sarin, Shiv Kumar, additional, Nagral, Abha, additional, Asrani, Sumeet, additional, Fallahzadeh, Mohammad Amin, additional, Albhaisi, Somaya, additional, Eapen, CE, additional, Goel, Ashish, additional, Duseja, Ajay Kumar, additional, Saraya, Anoop, additional, Yegurla, Jatin, additional, Rela, Mohd., additional, Jothimani, Dinesh, additional, Lohoues, Marie Jeanne, additional, Allah, Belimi Hibat, additional, Cabello, Ricardo, additional, Bhavani, Ruveena, additional, Nik Arsyad, Nik MA, additional, Treeprasertsuk, Sombat, additional, Wejnaruemarn, Salisa, additional, Perez Hernandez, Jose Luis, additional, Zazueta, Godolfino Miranda, additional, Rajoriya, Neil, additional, Faulkes, Rosemary, additional, Yıldırım, Abdullah Emre, additional, Barutcu, Sezgin, additional, Kulkarni, Anand, additional, Sharma, Mithun, additional, Reddy, Rajender, additional, Rahematpura, Suditi, additional, Danielle, Adebayo, additional, Kennedy, James, additional, Gunduz, Feyza, additional, Aslan, Rahmi, additional, Arora, Anil, additional, Kumar, Ashish, additional, Allam, Dalia, additional, Kumar Patwa, Yashwi Haresh, additional, Castillo, Mauricio, additional, Tan, Hiang Keat, additional, Lun, Liou Wei, additional, Vargas, Hugo E., additional, Bayne, David, additional, Thuluvath, Paul J., additional, Sheshadri, Somya, additional, Haveri, Ajay, additional, Keaveny, Andrew, additional, Shaw, Jawaid, additional, Okeke, Edith, additional, David, Nyam P, additional, Aravinthan, Aloysious, additional, Venkatachalapathy, Suresh Vasan, additional, Sonavane, Amey, additional, Desalegn, Hailemichael, additional, Fisseha, Henok, additional, Bettinger, Dominik, additional, Schultheiss, Michael, additional, Biggins, Scott, additional, Filipek, Natalia, additional, Leith, Damien, additional, Forrest, Ewan, additional, González-Huezo, Maria Sarai, additional, Velazquez, René Malé, additional, Made, Lilian Torres, additional, Yung, Diana, additional, Karasu, Zeki, additional, Cao, Zhujun, additional, Katzman, Helena, additional, Rabinowich, Liane, additional, Benitez, Carlos, additional, Rojo, Andres Duarte, additional, Marciano, Sebastián, additional, Gandotra, Akash, additional, Bush, Brian, additional, Thacker, Leroy, additional, and Choudhury, Ashok, additional

Published
2022
Full Text
View/download PDF

46. CLEARED Global consortium results highlight regional variation and need for equity in inpatient outcomes in hospitalized patients with Chronic Liver Disease

Author

Bajaj, Jasmohan S., primary, Kamath, Patrick S., additional, Wong, Florence, additional, Hayes, Peter, additional, Idilman, Ramazan, additional, Torre, Aldo, additional, Topazian, Mark, additional, George, Jacob, additional, Álvares-da-Silva, Mario Reis, additional, Xie, Qing, additional, Sarin, Shiv Kumar, additional, Nagral, Abha, additional, Haveri, Ajay, additional, Asrani, Sumeet, additional, Fallahzadeh, Mohammad Amin, additional, Albhaisi, Somaya, additional, Reddy, Rajender, additional, Rahematpura, Suditi, additional, Lohoues, Marie Jeanne, additional, Allah, Belimi Hibat, additional, Cabello, Ricardo, additional, Bhavani, Ruveena, additional, Nik Arsyad, Nik MA, additional, Treeprasertsuk, Sombat, additional, Wejnaruemarn, Salisa, additional, Perez Hernandez, Jose Luis, additional, Zazueta, Godolfino Miranda, additional, Rajoriya, Neil, additional, Faulkes, Rosemary, additional, Adebayo, Danielle, additional, Kennedy, James, additional, Yıldırım, Abdullah Emre, additional, Barutcu, Sezgin, additional, Eapen, CE, additional, Goel, Ashish, additional, Duseja, Ajay Kumar, additional, Saraya, Anoop, additional, Yegurla, Jatin, additional, Gandotra, Akash, additional, Rela, Mohd., additional, Jothimani, Dinesh, additional, Kulkarni, Anand, additional, Sharma, Mithun, additional, Sonavane, Amey, additional, Vargas, Hugo E., additional, Bayne, David, additional, Gunduz, Feyza, additional, Aslan, Rahmi, additional, Arora, Anil, additional, Kumar, Ashish, additional, Keaveny, Andrew, additional, Thuluvath, Paul J., additional, Sheshadri, Somya, additional, Allam, Dalia, additional, Kumar Patwa, Yashwi Haresh, additional, Castillo, Mauricio, additional, Tan, Hiang Keat, additional, Lun, Liou Wei, additional, Shaw, Jawaid, additional, Okeke, Edith, additional, David, Nyam P, additional, Yung, Diana, additional, Biggins, Scott, additional, Filipek, Natalia, additional, Rojo, Andres Duarte, additional, Benitez, Carlos, additional, Marciano, Sebastián, additional, Desalegn, Hailemichael, additional, Fisseha, Henok, additional, Katchman, Helena, additional, Rabinowich, Liane, additional, Velazquez, René Malé, additional, Made, Lilian Torres, additional, González-Huezo, Maria Sarai, additional, Aravinthan, Aloysious, additional, Venkatachalapathy, Suresh Vasan, additional, Leith, Damien, additional, Forrest, Ewan, additional, Karasu, Zeki, additional, Bettinger, Dominik, additional, Schultheiss, Michael, additional, Cao, Zhujun, additional, Bush, Brian, additional, and Thacker, Leroy, additional

Published
2022
Full Text
View/download PDF

48. The spatial distribution and detailed composition of infiltrating immune cells define autoimmune- and checkpoint-therapy associated hepatitis

Author

Krimmel, Laurenz, primary, Salie, Henrike, additional, Killmer, Saskia, additional, Lago, Marilyn Salvat, additional, Rana, Nisha, additional, Bronsert, Peter, additional, Rafei-Shamsabadi, David, additional, Meiss, Frank, additional, Ehmer, Ursula, additional, Krackhardt, Angela, additional, Schwabenland, Marius, additional, Prinz, Marco, additional, Neumann-Haefelin, Christoph, additional, Hofmann, Maike, additional, Schultheiss, Michael, additional, Thimme, Robert, additional, Mogler, Carolin, additional, and Bengsch, Bertram, additional

Published
2022
Full Text
View/download PDF

50. IMMUNIB trial (AIO-HEP-0218/ass): A single-arm, phase II study evaluating safety and efficacy of immunotherapy nivolumab in combination with lenvatinib in advanced-stage hepatocellular carcinoma (HCC).

Author

Vogel, Arndt, primary, Siegler, Gabriele Margareta, additional, Siebler, Jurgen, additional, Lindig, Udo, additional, Schultheiß, Michael, additional, Müller, Tobias, additional, Simon, Henry, additional, Jöckel, Christiane, additional, Mueller, Daniel Wilhelm, additional, Al-Batran, Salah-Eddin, additional, Saborowski, Anna, additional, and De Toni, Enrico N, additional

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results